Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | NMT1 | P30419 | 10/20 | 0.38 |
| ▸ | NMT2 | O60551 | 9/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.35 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18760195 | 0.99 | EPHX1 (0.42) | EPHX1NMT1NMT2EPHX2HDAC3 | |
| SCHEMBL18760191 | 0.95 | NMT1 (0.44) | EPHX1NMT1NMT2GRIN1GRIN2A | |
| SCHEMBL23840117 | 0.94 | NMT1 (0.40) | EPHX1NMT1NMT2 | |
| SCHEMBL22223575 | 0.92 | EPHX1 (0.41) | EPHX1NMT1NMT2EPHX2HDAC1 | |
| SCHEMBL18785521 | 0.85 | NMT1 (0.37) | NMT1NMT2 | |
| SCHEMBL20634648 | 0.84 | NMT1 (0.42) | NMT1NMT2EPHX2 | |
| SCHEMBL23840130 | 0.84 | NMT1 (0.42) | NMT1NMT2EPHX2 | |
| SCHEMBL20633489 | 0.84 | NMT1 (0.41) | NMT1NMT2 | |
| SCHEMBL20633487 | 0.82 | NMT1 (0.41) | NMT1NMT2GRIN1GRIN2A | |
| SCHEMBL18785522 | 0.82 | NMT1 (0.39) | NMT1NMT2GRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170112941-A1 | VE-CADHERIN BINDING BIOCONJUGATE | SYMIC IP, LLC | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112941-A1 | VE-CADHERIN BINDING BIOCONJUGATE | EPCAM, CDH1, VCAM1 | EPHX1 2084/4885NMT1 364/4885NMT2 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.